Exomind (rTMS) Treatment

Exomind® is an rTMS (repetitive Transcranial Magnetic Stimulation) system used to deliver non-invasive, drug-free brain stimulation for the treatment of depression and, increasingly, a range of other neuropsychiatric conditions. Using ExoTMS® technology, it applies focused magnetic pulses to specific, targeted brain regions to help restore healthy brain activity, without surgery, sedation, or systemic medication side effects.

rTMS is not a new or experimental concept — it has been FDA-cleared for treatment-resistant depression since 2008, and for obsessive-compulsive disorder since 2018, with a substantial and growing body of peer-reviewed clinical evidence behind it. Dr. Muhammad Shoaib Zafar, Consultant Psychiatrist, Assistant Professor of Psychiatry at King Edward Medical University, and Addiction Psychiatrist, offers Exomind treatment in Pakistan as part of a comprehensive, evidence-based approach to psychiatric care.

Exomind is an rTMS device system that delivers repetitive Transcranial Magnetic Stimulation using ExoTMS technology — a coil positioned against the scalp that generates focused, rapidly alternating magnetic pulses. These pulses pass painlessly through the skull and induce small electrical currents in targeted regions of the brain's cortex, most commonly the dorsolateral prefrontal cortex (DLPFC), a region strongly implicated in mood regulation.

As with any medical device, patients considering treatment should confirm the specific regulatory clearance, certification, and import/registration status of the exact Exomind system in use directly with the treating clinic, since device-specific documentation can be updated by manufacturers over time.

Repetitive Transcranial Magnetic Stimulation (rTMS) is a well-established form of neuromodulation — a broader category of treatments that work by directly influencing the activity of specific brain circuits, rather than acting throughout the body as oral medications do.

Depression and several other psychiatric conditions are associated with underactivity or dysregulation in specific brain circuits, particularly involving the DLPFC and its connections to deeper limbic structures involved in mood and emotional regulation. By repeatedly stimulating these circuits over a structured course of treatment, rTMS is believed to promote neuroplasticity — the brain's capacity to strengthen and reorganise neural connections — helping to restore healthier patterns of brain activity.

Exomind treatment does not involve any medication, sedation, or anaesthesia. Sessions are delivered on an outpatient basis, typically lasting around 20-40 minutes, after which patients can resume normal daily activities immediately, including driving themselves home.

rTMS has an established safety profile when delivered by trained clinical staff following standard screening protocols. The most common side effects are mild scalp discomfort and headache during or shortly after treatment. Full contraindications, screening requirements, and safety considerations are detailed on our dedicated Exomind Safety page.

rTMS for treatment-resistant depression is supported by numerous randomised controlled trials and meta-analyses, and is recognised in clinical guidelines internationally, including recommendations from bodies such as the UK's NICE and the American Psychiatric Association. Evidence for other indications varies considerably in strength — some (such as OCD and smoking cessation) have specific regulatory clearance and solid trial evidence, while others remain areas of active, ongoing research. Our dedicated Research page summarises the evidence base in more detail.

rTMS is not effective for every patient, and, like any treatment, response varies between individuals. It is not a first-line treatment for mild depression, is not typically used as a sole emergency intervention for acute crises, and — for several of the conditions discussed on this site — remains an emerging, actively researched application rather than an established, guideline-endorsed indication. We aim to present the evidence honestly for each condition discussed, distinguishing clearly between well-established and investigational uses.

Reviewed by Dr. Muhammad Shoaib Zafar — Consultant Psychiatrist, Assistant Professor of Psychiatry at King Edward Medical University, and Addiction Psychiatrist.

This content is informed by peer-reviewed clinical literature and guidance from recognised bodies including the American Psychiatric Association (APA) and the UK's NICE guidelines, and is provided for general educational purposes. It does not replace an individual psychiatric assessment, and does not constitute a guarantee of treatment outcome. Device-specific regulatory and certification details should be confirmed directly with the clinic.